# Peter Noymer

> Peter Noymer is the Executive Chairman and CEO of ForCast Orthopedics, a Denver-based development-stage company building a wearable system that pumps antibiotics straight into infected artificial joints. An MIT-trained mechanical engineer with more than two decades turning lab concepts into shipped pharmaceutical and device products, he has previously run or steered ophthalmology, cardiopulmonary and digital-health ventures, several of which were acquired by Novartis, United Therapeutics and Grupo Ferrer. At ForCast he has landed FDA Orphan Drug and Qualified Infectious Disease Product designations, a Series A led by a renowned orthopedic surgeon, and a 2026 MedTech Innovator slot.

- **Role:** Executive Chairman and CEO at ForCast Orthopedics, Inc.
- **Organizations:** ForCast Orthopedics, Inc., PyrAmes, Inc., 153 Therapeutics, Kedalion Therapeutics, SteadyMed Therapeutics, Alexza Pharmaceuticals, Aradigm Corporation
- **Nationality:** American
- **Education:** BSE, Mechanical and Aerospace Engineering, Princeton University, MS, Mechanical Engineering, Massachusetts Institute of Technology, PhD, Mechanical Engineering, Massachusetts Institute of Technology
- **Known for:** Secured FDA Orphan Drug designation for ForCast's lead program FC001 (gram-positive PJI), Secured FDA Qualified Infectious Disease Product (QIDP) designation for FC002 (gram-negative PJI), Closed the initial tranche of ForCast's Series A, led by orthopedic surgeon-entrepreneur Charles A. DeCook, MD

## Career timeline

- **1990s-2000s** — Research and management roles at Aradigm Corporation, working on pulmonary drug delivery (AERx system)
- **2000s** — VP of Product R&D at Alexza Pharmaceuticals (later acquired by Grupo Ferrer)
- **2013-2017** — CTO then COO at SteadyMed Therapeutics (later acquired by United Therapeutics)
- **2017-2019** — CEO of Kedalion Therapeutics, a clinical-stage ophthalmology company (acquired by Novartis)
- **2021** — Became Executive Chairman of the Board at PyrAmes, a Stanford digital-health spinout
- **ongoing** — Co-founder and CEO of 153 Therapeutics, a UCSF spinout developing small-molecule CNS therapeutics
- **ongoing** — Executive Chairman and CEO of ForCast Orthopedics (founded 2017)
- **2025-08** — Led initial close of ForCast's Series A financing, with OrthoInnovations LLC as lead investor
- **2025-09** — Announced agreement with KORU Medical Systems to use the FreedomEDGE infusion system
- **2025-11** — FDA granted QIDP designation to ForCast's second program, FC002 (tobramycin via WIIS)
- **2026** — ForCast selected for the MedTech Innovator accelerator cohort

## Achievements

- Secured FDA Orphan Drug designation for ForCast's lead program FC001 (gram-positive PJI)
- Secured FDA Qualified Infectious Disease Product (QIDP) designation for FC002 (gram-negative PJI)
- Closed the initial tranche of ForCast's Series A, led by orthopedic surgeon-entrepreneur Charles A. DeCook, MD
- ForCast selected for the competitive 2026 MedTech Innovator cohort (65 of 1,800+ applicants)
- Built and led multiple companies acquired by Novartis, United Therapeutics and Grupo Ferrer
- More than twenty years developing pharmaceutical and medical-device products from concept to market

## Latest updates

- **2026-01** — ForCast Orthopedics selected for the 2026 MedTech Innovator accelerator cohort and slated to present at the Wilson Sonsini conference.
- **2025-11** — FDA granted QIDP designation for FC002, pairing ForCast's WIIS platform with tobramycin for gram-negative PJI.
- **2025-09** — Signed agreement with KORU Medical Systems to leverage its FreedomEDGE infusion system.
- **2025-08** — Announced initial close of Series A financing led by OrthoInnovations LLC.

## Links

- Website: https://forcastortho.com
- LinkedIn: http://www.linkedin.com/in/peter-noymer-3832b26

---

Profile page: https://yespress.io/peter-noymer
Published by YesPress — https://yespress.io
Last updated: 2026-06-08